Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Thrombectomy doesn't help—and may harm—in smaller stroke vessels. A pooled analysis of three randomized trials found that mechanical thrombectomy offered no improvement in 90-day functional outcomes for medium or distal vessel occlusion strokes, while more than doubling the risk of symptomatic brain bleeding. A secondary DISTAL trial analysis adds nuance: among patients ineligible for clot-busting drugs, those with more severe strokes (NIHSS >10) may still see some benefit.
Thrombectomy—the gold standard for large-vessel stroke—doesn't appear to translate to smaller, more distal brain vessel occlusions. A systematic review and pooled analysis of three randomized trials (DISTAL, ESCAPE-MeVO, and interim DISCOUNT) found that adding mechanical thrombectomy to standard medical therapy did not improve 90-day functional independence in medium or distal vessel occlusion (MeVO/DiVO) stroke. Worse, it significantly raised the risk of symptomatic brain bleeding.
A secondary analysis of the DISTAL trial adds important nuance: while prior thrombolysis (IVT) status didn't change thrombectomy's effect, stroke severity did. Among patients ineligible for IVT, those with a baseline NIHSS score above 10 showed increasingly better outcomes with thrombectomy—suggesting that deficit severity, not vessel size alone, may be the key selection variable going forward.
By the Numbers:
Why it matters: These findings challenge the assumption that thrombectomy's proven benefits in large-vessel strokes automatically extend to smaller vessels. For clinicians, the takeaway is clear: routine thrombectomy for MeVO/DiVO strokes isn't supported by current evidence, and the bleeding risk is real. The focus now shifts to identifying which patients—likely those with more severe deficits or specific occlusion anatomy—might still benefit.